All In Biotech

Drug Trial Radar · NCT01931566

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects

Last checked: Nov 20, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,494 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,494

Actual

Start

Aug 1, 2013

Primary completion

Jul 24, 2018

Study completion Sep 6, 2018

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Zinfandel Pharmaceuticals Inc.
First posted
Aug 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 65 years, up to 83 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.

Conditions

  • Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

  • PioglitazoneDrug

    Pioglitazone SR tablets

  • Pioglitazone placeboDrug

    Pioglitazone placebo-matching tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease (MCI-AD) for Placebo-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, Low-risk, Non-Hispanic/Latino Caucasian ParticipantsTime frame: Baseline to the end of study (approximately up to 5 years)
  2. Time to Diagnosis of MCI Due to AD for Pioglitazone-treated, High-risk, Non-Hispanic/Latino Caucasian Participants Versus Placebo-treated, High-risk, Non-Hispanic/Latino, Caucasian ParticipantsTime frame: Baseline to the end of study (approximately up to 5 years)

Locations

55 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sun City, Arizona

  • Site not named

    Long Beach, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Delray Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Lady Lake, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Merritt Island, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Elk Grove, Illinois

  • Site not named

    Elk Grove Village, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Farmington Hills, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Marlton, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Concord, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Charleston, South Carolina

  • Site not named

    Cordova, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Middleton, Wisconsin

  • Site not named

    North Ryde, New South Wales, Australia

  • Site not named

    Southport, Queensland, Australia

  • Site not named

    West Heidelberg, Victoria, Australia

  • Site not named

    Nedlands, Western Australia, Australia

  • Site not named

    Berlin, Germany

  • Site not named

    Stuttgart, Baden-Wurttemberg, Germany

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.